Researchers from the Oncology Department of Tianjin Medical University Cancer Hospital in China recently published a study in Advanced Functional Materials announcing the creation of a new nano-carrier for pancreatic cancer treatments.
Bankrupt cell therapy firm Dendreon has attracted more suitors according to stalking horse bidder Valeant, which upped its offer for the Provenge (sipuleucel-T) developer to $400m this week.
Sotio has selected local CRO Accord Research to carry out Phase I/II trials on its dendritic cell vaccines to treat patients with lung cancer in the Czech Republic.
Cancer and infectious disease immunotherapy developer Argos Therapeutics is collaborating with Saint-Gobain’s Performance Plastics division, to design, integrate and scale production of a range of disposables for use in the manufacturing of Argos’ lead...
Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract manufacturing of the castration-resistant prostate cancer drug Xofigo (radium Ra 223 dichloride).
A magnetic pulse technology that can align and push nanoparticles to points distant to magnet surfaces could finally make magnets attractive for deep tissue drug delivery according to researchers.
Sweden is an expert in high-tech trials but stalls in the recruitment phase, says the academic trying to change all that with a database of biomarkers matching patients to studies.
Horizon is already making plans for the research model company it acquired last month, announcing today it will offer patient-derived xenograft (PDX) models for breast cancer under the Sage Labs name.
Swiss-based Sellas Life Sciences Group has signed a definitive master service agreement with CRO Pharmaceutical Product Development (PPD) to advance and expand clinical and regulatory development.
The ability to pinpoint radiotherapy in animal testing could give failed cancer drug candidates a new lease of life, says preclinical CRO (contract research organisation) Crown Biosciences.
Crown Biosciences has partnered with China’s biggest producer of mutant mice to build better experimental models for its cancer research sponsors, as part of its $26.5m (£16m) venture funding.
Chemists at MIT have created a triple warhead against cancer. They believe theirs is the first example a polymer nanoparticle which carries a precise ratio of three drugs that can be released in response to three distinct triggers.
Researchers in Switzerland have devised a form of gold nanoparticle that shows promise as a weapon against tumours and as a delivery vehicle for drugs.
Karyopharm Therapeutics has selected CRO Clinipace to help discover first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
CRO Evotec AG will help Debiopharm identify and develop novel compounds with the potential to treat multiple forms of solid tumours and leukaemias with defined genetic alterations under a collabortation announced today.
As biopharma companies look to develop cancer therapies more quickly, some are turning to CROs with the hopes of using surrogate endpoints to expedite US FDA approval.
A new study published in the Institute of Physics Science reveals that Chinese researchers have developed gold nanoparticles that may help deliver cancer treatments to specifically targeted cells.
PharmaCell, the CMO that makes Provenge for Dendreon in Europe, has agreed to buy a facility from TiGenix to add capacity and a manufacturing contract for a second commercial product.
All the obvious cancer targets have been found according to Horizon Discovery, which last week agreed to help AstraZeneca find some new ones using isogenic pairs of oncology relevant cells.
AstraZeneca says it would never outsource the manufacture of Zoladex after announcing plans to invest £120m ($190m) in a fifth production facility for the blockbuster cancer drug.
Discovery CRO Crown Biosciences has partnered with X-ray drug research specialist Xstrahl Life Sciences in a deal designed to make preclinical models that more accurately reflect clinical use of radiotherapy.
Quintiles is looking into a new way of using biomarkers to speed the process of selecting patients for trials and new treatments, Quintiles Chief Medical and Scientific Officer Dr. Jeff Spaeder told us.
Amgen spent $10.4bn (€7.8bn) this week on Onyx Pharmaceuticals, but AstraZeneca and Johnson & Johnson have also opened up their wallets this week – welcome to in-Pharmatechnologist.com’s merger & acquisition round-up.
Canadian contract manufacturing and testing firm Garmen Laboratories will be acquired by Cancer drug developer Advanomics Corp in a deal announced today.
US CRO Crown BioSciences has acquired Precos citing the UK contractor’s preclinical oncology services and presence in the European market as the key drivers.
Over the next 10 years CMO Corgenix will contract manufacture EDP Biotech’s diagnostic test to detect the early stages of colon cancer, the companies agreed last week.
Ash Stevens is planning to expand its API manufacturing facility in Michigan, which was recently approved by the US FDA to produce Ariad Pharmaceuticals’ oncology drug Iclusig (ponatinib).
Following a wave of recent investment in ADC production, Synthon has opened an ADC manufacturing facility in Nijmegen, Netherlands, to help bring its first preclinical ADC program to clinical trials by 2014.
Hollow nano shells capable of holding both cancer fighting drugs and immune-system boosters could be the solution to oncology’s greatest delivery riddle, according to Yale University researchers.
A new discovery platform for RNA delivery vehicles could mean 20 per cent more efficiency for guiding nanoparticles into cancer cells, say researchers.
in-PharmaTechnologist presents its round-up of the latest drug delivery research developments in the pharmaceutical world, including tumour targeting peptides and lipid nanoparticle drug-delivery technology.
in-PharmaTechnologist presents its weekly line-up of the latest appointments in the pharmaceutical industry, including news from Genesis, Acino and Pharmalink AB.
